A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety of ISIS-STAT3Rx in patients with Advanced Cancers
Approximately 28 days after last dose of ISIS -STAT3Rx
No
United States: Food and Drug Administration
ISIS 481464-CS1
NCT01563302
February 2012
July 2014
Name | Location |
---|---|
MD Anderson Cancer Center | Houston, Texas 77030-4096 |
Mayo Clinic | Rochester, Minnesota 55905 |
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
Washington University School of Medicine | Saint Louis, Missouri 63110 |
Yale Cancer Center | New Haven, Connecticut 06520-8028 |
Northwestern University | Chicago, Illinois 60611 |
Mayo Clinic Arizona | Scottsdale, Arizona 85259 |
Mary Crowley Cancer Research Centers | Dallas, Texas 75201 |
Moores UC San Diego Cancer Center | La Jolla, California 92093 |